🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06426953
Recruiting Observational

Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

NCT06426953 · tracked via the Priya Life Science China tracker
Sponsor
Xie Kangjie
Phase
Observational
Started
2024-05-20
Last updated
2025-09-29

Condition(s) studied

DiabetesPostoperative Delirium

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients

Eligibility

Sex
ALL
Min age
65 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥65 years 2. History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose 3. The ASA rating is Class I to III 4. The elderly patients of limited thoracic and abdominal tumor surgery Exclusion Criteria: 1. Refused to participate 2. Previous history of schizophrenia, epilepsy, Parkinson's disease 3. History of alcohol abuse or drug dependence 4. Patients with ASA grade IV and above 5. Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests 6. Participants in other clinical trials within the last two months 7. Patients with severe arrhythmia or cardiac dysfunction(EF\<40%) 8. There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants 9. History of cerebrovascular disease or brain surgery or trauma 10. Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
The People's hospital of Qiannan Duyun Guizhou Not Yet Recruiting
Zhejiang Cancer Hospital Hangzhou Zhejiang Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06426953 on ClinicalTrials.gov ↗ ← All trials in China